2020 On-site
20/20 Onsite is a private Boston-based healthcare services company that delivers point-of-need ophthalmic assessments for pharmaceutical and biotech clinical trials via a nationwide fleet of Mobile Vision Clinics, Pods, and Clinical Suites, serving trial sponsors, CROs, and select corporate clients.
- Company typePrivate
- Founded2014
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What 2020 On-site does
20/20 Onsite is a privately held Boston-based healthcare services company that provides point-of-need ophthalmic assessments for clinical trials sponsored by pharmaceutical and biotechnology companies, as well as contract research organizations. Founded in 2014 by Howard Bornstein as a corporate wellness eye-care provider, the company pivoted to clinical research during the COVID-19 pandemic in 2020 after a major pharmaceutical sponsor engaged it to rescue a disrupted trial. Since the pivot, the company has supported 45+ clinical trials across 48 states and performed more than 100,000 point-of-need eye exams.
The company's core offering rests on three physical delivery modalities: Mobile Vision Clinics (fully equipped vehicles), Mobile Vision Pods (semi-permanent modular spaces), and Mobile Clinical Suites (portable equipment and staff for existing facilities). All units use calibrated, validated equipment compliant with 21 CFR Part 11, GCP, HIPAA, and GDPR standards, and clinical staff average 11+ years of ophthalmic experience. The service portfolio spans study design and protocol consultation, patient prescreening and enrollment, exam integration at existing sites, patient retention, trial rescue, and post-marketing surveillance, with each engagement generating custom contract pricing based on scope, geography, and duration. The company maintains both a clinical trial solutions business and a smaller corporate/community vision-care program (the Vision for Boston initiative has served over 5,000 children since 2015).
Revenue is generated through negotiated multi-year professional services contracts with pharmaceutical sponsors and CROs, supplemented by corporate wellness engagements. Sales are driven by enterprise field sales to clinical operations leaders at sponsors and CROs, supported by thought-leadership content (the 'Eyes on Research' blog, webinars, case studies), industry conference participation, and earned media. The company has raised approximately $23.8 million in disclosed funding across rounds from 2014 through 2021, with an $8 million growth financing closing in May 2021.
2020 On-site firmographics
Firmographics- Name
- 2020 On-site
- Legal name
- 20/20 Onsite
- Website
- https://2020onsite.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 20/20 Onsite is a private Boston-based healthcare services company that delivers point-of-need ophthalmic assessments for pharmaceutical and biotech clinical trials via a nationwide fleet of Mobile Vision Clinics, Pods, and Clinical Suites, serving trial sponsors, CROs, and select corporate clients.
- Ownership category
- akta.pro rank
2020 On-site industry classification
Industry- Product category
- Clinical Trial Ophthalmic Assessment Services
- NAICS
- Offices of Physicians (6211), Diagnostic Imaging Centers (621512)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
Keywords
Where 2020 On-site is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
2020 On-site business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Clinical Trial Ophthalmic Assessment Services: 20/20 Onsite provides point-of-need ophthalmic assessments for clinical trial sponsors and CROs. Revenue is generated through service contracts for Phase 1-4 clinical trials, covering protocol consultation, prescreening, enrollment support, endpoint assessments, and post-marketing surveillance. Pricing varies based on trial scope, number of assessments, geographic coverage, and duration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Trial-specific service contracts with custom pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
2020 On-site product offering
Product offeringCore offering
20/20 Onsite delivers point-of-need ophthalmic assessment services for clinical trials through three mobile delivery modalities: fully-equipped Mobile Vision Clinics (MVCs), semi-permanent Mobile Vision Pods (MVPs), and Mobile Clinic Suites (MCSs) deployed at existing facilities. The company provides certified ophthalmic assessments (OCT, BCVA, slit lamp, fundus photography, visual field, etc.) along with protocol consultation, prescreening, enrollment support, endpoint assessments, and post-marketing surveillance for Phase 1-4 trials. Services are contracted directly with pharmaceutical sponsors and CROs, executing ocular assessments at trial participant locations across 48 states.
Product overview
20/20 Onsite is a specialized healthcare services company providing point-of-need ophthalmic clinical trial solutions through three innovative delivery modalities: Mobile Vision Clinics (MVCs), Mobile Vision Pods (MVPs), and Mobile Clinic Suites (MCSs). The company offers a comprehensive portfolio of services including study design and protocol review, patient prescreening and enrollment, seamless exam integration, patient retention programs, and post-marketing surveillance. Their core offering centers on bringing certified ophthalmic assessments directly to trial participants wherever they are located, eliminating geographical barriers and reducing patient burden. The platform supports Phase 1-4 clinical trials and addresses various therapeutic areas including CNS, ophthalmic, respiratory, and rare diseases. Key assessment capabilities include OCT, fundus photography, visual acuity testing, slit lamp biomicroscopy, and intraocular pressure measurements, all performed by certified clinical professionals with an average of 11+ years of ophthalmic experience.
Differentiator
Problem solved
Functional benefit
Products and services
- Mobile Vision Clinic (MVC) Fully-equipped clinics on wheels providing comprehensive ophthalmic assessments for clinical trial participants at their homes, workplaces, or other convenient locations. Specially-equipped, fully-staffed vehicles have traveled over 200,000 miles across 48 states.
- Mobile Vision Pod (MVP) Semi-permanent, modular examination spaces that can be set up and customized per study requirements, offering a cost-effective solution for on-site ophthalmic assessments at clinical trial locations.
- Mobile Clinic Suite (MCS) Portable solutions bringing ophthalmic equipment and certified staff to existing exam rooms and suitable facilities, seamlessly integrating with clinic workflows for point-of-need assessments.
- Clinical Trial Solutions for Phase 1-3 End-to-end mobile ophthalmic solutions supporting every phase of clinical trials from protocol consultation and precision prescreening to enrollment acceleration and patient retention.
- Post Marketing & Real World Evidence Solutions
Quantifiable outcome
- Patient dropout rates reduced by 70% compared to industry average (achieving 9% vs 30% industry standard)
- +5 more outcomes
Companies that use 2020 On-site
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
2020 On-site technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
2020 On-site partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- American Diabetes AssociationminorPartnership for ADA Step Out: Walk to Stop Diabetes events, with 20/20 Onsite mobile vision clinic conducting free eye screenings to promote diabetes-related eye health awareness.
- Sano GeneticsminorPartnership to boost access to specialist eye care and related research for US patients, combining genetic testing capabilities with ophthalmic assessment services.
- MyzeminorPartnership to change daily eye care for over 65,000 patients through integrated mobile vision clinic and daily eye care platform services.
- The Vision Council FoundationminorPartnership to provide vision screenings at Boston Public Library locations, expanding access to eye care for underserved populations in partnership with The Vision Council Foundation.
- Warby ParkerminorPartnership supporting Vision for Boston program, with Warby Parker providing eyewear for underprivileged students receiving eye exams through the mobile clinic program.
- Greater GiftminorPartnership to honor and celebrate clinical trial participants while providing eye exams to underserved children in the local community through coordinated Giving Back initiatives.
- Syneos HealthcoreSyneos Health, a leading fully integrated biopharmaceutical solutions organization, partnered with 20/20 Onsite to deploy Mobile Vision Clinics and Mobile Clinical Suites for Phase 1 clinical trial support. The partnership enabled ocular safety assessments at research sites lacking specialized equipment and personnel, with 65+ patients successfully enrolled across multiple studies.
- AGTC (Applied Genetic Technologies Corporation)coreAGTC launched a nationwide mobile vision testing program with 20/20 Onsite for patients enrolled in ongoing Phase 1/2 clinical trials for X-linked Retinitis Pigmentosa and Achromatopsia gene therapy treatments. The partnership enabled patient participation during COVID-19 travel restrictions.
- Boston Public SchoolscoreLong-running 'Vision for Boston' program providing free vision screenings, eye exams, and eyewear to over 5,000 underprivileged children. Funded through corporate office visit revenue, creating sustainable philanthropy model.
Scale indicators12 records
Recent moves9 records
Expansion highlights4 records
2020 On-site competitors and assessment
Company assessmentEmerging players
- Medable: Decentralized clinical trial technology provider; overlaps on the shift toward point-of-need trial execution but does not specialize in ophthalmic assessments.
- Science 37: Decentralized clinical trial platform enabling remote assessments; overlaps with 20/20 Onsite's mobile deployment thesis but covers multiple therapeutic endpoints, not specialized in ophthalmology.
Direct peers
- Clario: Clinical trial imaging and endpoint services provider with ophthalmic imaging capabilities, directly competing in the same specialized ophthalmic endpoint execution space as 20/20 Onsite.
- EyeCRO: Specialty ophthalmic clinical research organization providing ophthalmic clinical trial services, overlapping directly with 20/20 Onsite's specialty CRO positioning for ocular endpoints.
- ORA Clinical Research: Specialty ophthalmic clinical research organization offering site and ophthalmic assessment services for trials, directly comparable to 20/20 Onsite's focus on ocular endpoints.
Broad incumbents
- Syneos Health: Large full-service CRO and 20/20 Onsite's named partner for Phase 1 ocular safety work; broader portfolio across clinical development but overlapping on ophthalmic trial execution.
- Worldwide Clinical Trials: Mid-size global CRO with strong CNS and metabolic therapeutic area presence; competes for the same pharma sponsors running trials with ocular safety endpoints.
- Medpace: Mid-to-large CRO with therapeutic-area depth including CNS and ophthalmology, overlapping on trials where ocular endpoints are required.
- ICON plc: Major global CRO with ophthalmic and CNS trial experience; broader service portfolio but overlapping on trials requiring ocular endpoint assessments.
- IQVIA: Largest global CRO with broad ophthalmic trial capabilities; competes for the same pharma sponsor budgets as 20/20 Onsite but lacks its point-of-need mobile specialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
2020 On-site social profiles
Digital presence2020 On-site compliance and trust
Trust signalCompliance4 records
2020 On-site financial estimates
Financial estimateRevenue estimate
Valuation estimate
2020 On-site leadership team
Management profileNumber of profiles
Profiles13 records
2020 On-site funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
2020 On-site M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 2020 On-site
What does 2020 On-site do?
20/20 Onsite delivers point-of-need ophthalmic assessment services for clinical trials through three mobile delivery modalities: fully-equipped Mobile Vision Clinics (MVCs), semi-permanent Mobile Vision Pods (MVPs), and Mobile Clinic Suites (MCSs) deployed at existing facilities. The company provides certified ophthalmic assessments (OCT, BCVA, slit lamp, fundus photography, visual field, etc.) along with protocol consultation, prescreening, enrollment support, endpoint assessments, and post-marketing surveillance for Phase 1-4 trials. Services are contracted directly with pharmaceutical sponsors and CROs, executing ocular assessments at trial participant locations across 48 states.
Is 2020 On-site a public or private company?
2020 On-site is a private company. It is classified as venture growth investor backed and is currently operating.
When was 2020 On-site founded?
2020 On-site was founded in 2014. It employs 11 to 50 people.
Where is 2020 On-site based?
2020 On-site is headquartered in Boston, United States, in the North America region.
How does 2020 On-site make money?
One revenue line is on record: clinical Trial Ophthalmic Assessment Services.
Who are 2020 On-site's main competitors?
Emerging players on record are Medable and Science 37. Direct peers are Clario, EyeCRO and ORA Clinical Research. Broad incumbents are Syneos Health, Worldwide Clinical Trials, Medpace, ICON plc and IQVIA.
Does 2020 On-site have an API?
No public API is recorded for 2020 On-site.
What industry is 2020 On-site in?
2020 On-site's product category is Clinical Trial Ophthalmic Assessment Services. Its primary akta.pro industry code is HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 6211 and its SIC code is 8011.